Abstract
Variants in G protein-coupled inward rectifier K+ channels 4 (GIRK4 also known as KCNJ5) gene are associated with primary aldosteronism, which is the most common cause of secondary hypertension. The KCNJ5 rs2604204 variant was shown to be common (minor allele frequency=32.5%) in Chinese patients with essential hypertension (EH). The relationship between KCNJ5 variant and plasma aldosterone (ALD) levels in EH patients has not been reported. We collected 229 patients with newly diagnosed EH without any antihypertensive agents. According to the median standing plasma ALD, high-ALD and control groups were divided. Clinical data and blood samples were collected. KCNJ5 rs2604204 genotype was determined by PCR. The results showed that the levels of triglyceride, uric acid, insulin, insulin resistance (IR) index, renin, angiotensin I (Ang I), angiotensin II (Ang II), cortisol, 24 h mean systolic blood pressure (SBP) and daytime mean SBP were significantly increased in the high-ALD group than those in the control group, as well as 24 h s.d. of SBP and diastolic BP (DBP), and 24 h coefficient of variance of SBP and DBP. Notably, the distribution frequency of AC and CC genotypes, and the C allele of KCNJ5 were also significantly higher in the high-ALD group. Logistic regression analysis showed that the C allele of KCNJ5 rs2604204 was one risk factor for increased plasma ALD in Chinese EH patients (P=0.008, odds ratio=2.2 (95% confidence interval 1.2–4.1)). Our findings indicated that the variation of plasma ALD might be associated with increased IR and BP variability. Moreover, KCNJ5 rs2604204 polymorphism was related to increased plasma ALD level, but also plasma renin, Ang I and II levels in newly diagnosed, never-treated EH patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Calhoun DA . Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1: 1039–1045.
Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–41.
Newton-Cheh C, Guo CY, Gona P, Larson GM, Emalia JB, Wang TJ et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846–856.
Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 2013; 61 (4): 886–893.
Savard S, Amar L, Plouin PF, Steichen O . Cardiovascular complications associated with primary aldosteronism: a controlled crosssectional study. Hypertension 2013; 62: 331–336.
Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826–4833.
Zhang YJ, Li NF, Zhang JH, Xing WH, Li B . Correlation between plasma aldosterone concentration and left ventricular structure in hypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi 2013; 41 (7): 583–586.
Mulè G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C et al. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with metabolic syndrome. Am J Hypertens 2008; 21: 1055–1061.
Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK . Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010; 95: 1986–1990.
Hannemann A, Wallaschofski H, Lüdemann J, Völzke H, Markus MR, Rettig R et al. Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects. Atherosclerosis 2011; 219: 875–879.
Deo R, Yang W, Khan AM, Bansal N, Zhang X, Leonard MB et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 2014; 64 (1): 103–110.
Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W . Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31 (10): 1237–1247.
Ross DF . Recent milestones on the long and winding road from electrocortin to KCNJ5, GPER, and beyond. Hypertension 2014; 63: 19–21.
Li NF, Li HJ, Zhang DL, Zhang JH, Yao XG, Wang HM et al. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China. PLoS ONE 2013; 8 (1): e54051.
Liu LS Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39 (7): 579–615.
JCS Joint Working Group. Guidelines for the clinical use of 24-h ambulatory blood pressure monitoring (ABPM) (JCS 2010):–digest version. Circ J 2012; 76 (2): 508–519.
Kumagai E, Adachi H, Jacobs DR Jr, Hirai Y, Enomoto M, Fukami A et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 2011; 58 (6): 1043–1048.
Briet M, Schiffrin EL . The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011; 13 (2): 163–172.
Miura R, Nakamura K, Miura D, Miura A, Hisamatsu K, Kajiya M et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci 2006; 102 (3): 288–295.
Rutkowska-Zapała M, Suski M, Szatanek R, Lenart M, Węglarczyk K, Olszanecki R et al. Human monocyte subsets exhibit divergent angiotensin I-converting activity. Clin Exp Immunol 2015; 181 (1): 126–132.
Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G et al. Awake systolic blood pressure variability correlates with target organ damage in hypertensive subjects. Hypertension 2007; 50: 325–332.
Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Björklund-Bodegård K et al. Prognostic value of reading-to-reading blood pressure variability over 24 h in 8938 subjects from 11 populations. Hypertension 2010; 55 (4): 1049–1057.
Ozkayar N, Dede F, Akyel F, Yildirim T, Ateş I, Turhan T et al. Relationship between blood pressure varıability and renal activity of the renin-angiotensin system. J Hum Hypertens 2016; 30 (5): 297–302.
Grillo A, Bernardi S, Rebellato A, Fabris B, Bardelli M, Burrello J et al. Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary aldosteronism. J Clin Hypertens 2015; 17 (8): 603–608.
Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768–772.
Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592–598.
Zheng FF, Zhu LM, Nie AF, Li XY, Lin JR, Zhang K et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension 2015; 65 (3): 622–628.
van Leeuwen N, Caprio M, Blaya C, Fumeron F, Sartorato P, Ronconi V et al. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 2010; 56: 995–1002.
Ketsawatsomkron P, Stepp DW, Fulton DJ, Marrero MB . Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of protein tyrosine phosphatase-1B. Vascul Pharmacol 2010; 53 (3–4): 160–168.
Härdtner C, Mörke C, Walther R, Wolke C, Lendeckel U . High glucose activates the alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes in pancreatic β-cells. Int J Mol Med 2013; 32 (4): 795–804.
Li NF, Kang YA, Zhang DL, Wang HM, Zhang JH, Hu YR et al. Association between GIRK4 gene polymorphisms and insulin resistance in Xinjiang Uygur population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29 (6): 715–719.
Li N, Zhang D, Zhang J, Guo Y, Yan Z, Wang H et al. Influence of age on the association of GIRK4 with metabolic syndrome. Ann Clin Biochem 2012; 49: 369–376.
Hattangady NG, Karashima S, Yuan L, Ponce-Balbuena D, Jalife J, Gomez-Sanchez CE et al. Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production. J Mol Endocrinol 2016; 57 (1): 1–11.
Acknowledgements
We would like to express their sincere gratitude to all the study subjects for their voluntary participation and to all the staff of Hypertension Laboratory in Fujian Provincial Cardiovascular Disease Institute for their excellent assistance in data collection and conservation of samples. This work was supported by the Natural Science Foundation of Fujian Province (no 2014Y01010261) and Health Innovation Fund of Fujian (no 2012-CXB-5). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author contributions
Conceived and designed the experiments: HC. Performed the experiments: HW, CW and HC. Analysed the data: HW and CW. Contributed reagents/materials/analysis tools: HW and CW. Wrote the paper: HW, CW and HC.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wang, H., Weng, C. & Chen, H. Positive association between KCNJ5 rs2604204 (A/C) polymorphism and plasma aldosterone levels, but also plasma renin and angiotensin I and II levels, in newly diagnosed hypertensive Chinese: a case–control study. J Hum Hypertens 31, 457–461 (2017). https://doi.org/10.1038/jhh.2016.97
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2016.97